In a young‑to‑middle‑aged adult male with borderline low total testosterone, low‑normal free testosterone, mildly elevated creatine kinase, isolated mild AST elevation, low‑normal white blood cell count, high LDL‑cholesterol and markedly elevated lipoprotein(a), what are the appropriate management recommendations?

Management Recommendations for Young Adult Male with Borderline Low Testosterone and Cardiovascular Risk Factors

Do not initiate testosterone therapy in this patient, as the testosterone level of 365 ng/dL does not meet diagnostic criteria for hypogonadism, and treatment should focus aggressively on the markedly elevated cardiovascular risk from high LDL-cholesterol and lipoprotein(a). 1, 2

Testosterone Assessment and Management

Why Testosterone Therapy is NOT Indicated

Your total testosterone of 365.33 ng/dL falls above the diagnostic threshold for hypogonadism. The AUA guideline defines low testosterone as consistently <300 ng/dL on at least two early morning measurements 2. The ACP guidelines similarly use <320 ng/dL (11.1 nmol/L) as the threshold for "syndromic low testosterone" 1.

Critical diagnostic requirements NOT met:

• Total testosterone must be <300 ng/dL on two separate early morning measurements 2
• Clinical diagnosis requires both low testosterone levels and specific symptoms/signs 2
• Free testosterone of 13.60 pg/mL is low-normal but does not independently warrant treatment without confirmed low total testosterone

What to Do Instead

Repeat testosterone measurement: Obtain a second early morning (7-11 AM) total testosterone level to confirm whether levels are truly low 2. If the repeat value is also <300 ng/dL and the patient has specific symptoms (reduced libido, erectile dysfunction, decreased energy with other causes excluded), only then consider discussing testosterone therapy 1.

If testosterone therapy were indicated (which it currently is not), the ACP recommends discussing treatment only for sexual dysfunction improvement, not for energy, vitality, or physical function 1. Treatment should be reevaluated at 12 months and discontinued if no improvement 1.

Cardiovascular Risk Management: The Priority

LDL-Cholesterol: Immediate Action Required

Your LDL-cholesterol of 161 mg/dL requires aggressive lipid-lowering therapy. This is the most important modifiable risk factor in this patient.

Initiate high-intensity statin therapy immediately:

• Target LDL-C <70 mg/dL (ideally <55 mg/dL given multiple risk factors) 3
• Start atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily
• Consider combination therapy from the outset: statin + ezetimibe 10 mg daily to achieve rapid LDL-C reduction 4, 5

Rationale for aggressive approach:

• LDL-C 161 mg/dL represents significant cardiovascular risk
• Non-HDL cholesterol 162 mg/dL is also elevated
• Presence of markedly elevated Lp(a) (see below) compounds risk
• Modern evidence supports early intensive LDL-lowering rather than sequential "treat-to-fail" approaches 4, 5

Lipoprotein(a): Major Cardiovascular Risk Factor

Lipoprotein(a) of 103.44 mg/dL is markedly elevated (generally >50 mg/dL is considered high-risk). This is a causal, independent risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis 6.

Management implications:

• Lp(a) is genetically determined and not modifiable by lifestyle
• No specific Lp(a)-lowering therapies are currently approved
• This finding mandates even more aggressive LDL-C lowering to offset the elevated cardiovascular risk 6
• Target LDL-C should be <55 mg/dL, potentially <30 mg/dL if very high risk 6, 5
• PCSK9 inhibitors (evolocumab, alirocumab) can lower Lp(a) by 20-30% while dramatically reducing LDL-C and may provide particular benefit in patients with elevated Lp(a) 6, 5

Consider PCSK9 inhibitor therapy if LDL-C remains >70 mg/dL on statin + ezetimibe, given the markedly elevated Lp(a) 6, 5.

Triglycerides and Other Lipid Parameters

Triglycerides of 94 mg/dL are normal. HDL-cholesterol of 53 mg/dL is acceptable. The Apo B/Apo A1 ratio of 0.93 is borderline elevated, reflecting the high LDL burden.

Other Laboratory Findings

Creatine Kinase Elevation

CK of 674 U/L is mildly elevated (typically 2-3x upper limit of normal). Common causes:

• Recent exercise or physical activity (most common)
• Muscle injury
• Hypothyroidism (your TSH 2.96 is normal, ruling this out)

Management:

• Assess for recent physical activity, trauma, or intramuscular injections
• Recheck CK after 48-72 hours of rest
• If persistently elevated without explanation, consider muscle disorders
• Important: Baseline CK should be documented before starting statin therapy 7. If statin is started and myopathy symptoms develop (muscle pain, weakness), CK should be rechecked 7

Mild AST Elevation

AST 37.9 U/L with normal ALT 22.0 U/L and AST:ALT ratio of 1.72. The isolated mild AST elevation with normal ALT, normal GGT, normal alkaline phosphatase, and normal bilirubin suggests:

• Possible muscle source (AST is present in muscle; elevated CK supports this)
• Hemolysis (check if sample was hemolyzed)
• Not concerning for significant liver disease given normal other liver enzymes

Management:

• Likely related to muscle (given elevated CK)
• Recheck with CK after rest period
• Document baseline before statin initiation 7

Low-Normal White Blood Cell Count

Total leukocyte count of 3.10 thou/mm³ is at the lower end of normal. Absolute neutrophil count of 1.66 is adequate (>1.5 is generally safe). No action needed unless recurrent infections occur or counts decline further.

Kidney Function

Creatinine 1.15 mg/dL with eGFR 84 mL/min/1.73m² represents mild reduction in kidney function (CKD stage 2 if persistent). BUN 19.97 mg/dL is normal. No contraindication to statin therapy. Monitor kidney function periodically.

Monitoring Plan

If Statin Therapy Initiated (Recommended)

Baseline (before starting):

• Lipid panel (already done)
• CK, ALT, AST (already done; repeat CK after rest)
• HbA1c (already done: 4.6% - excellent)

Follow-up at 4-6 weeks:

• Fasting lipid panel to assess LDL-C response
• ALT, AST, CK
• Assess for muscle symptoms (pain, weakness, cramping)

Follow-up at 3 months:

• Fasting lipid panel
• If LDL-C not at goal (<70 mg/dL, ideally <55 mg/dL), intensify therapy by adding ezetimibe or increasing statin dose
• If LDL-C still not at goal on maximal statin + ezetimibe, consider PCSK9 inhibitor given elevated Lp(a)

Ongoing monitoring:

• Lipid panel every 3-6 months initially, then annually once stable 7
• ALT, AST, CK annually or if symptoms develop 7
• Repeat Lp(a) is not necessary (genetically determined, does not change) 6

If Testosterone is Rechecked and Confirmed Low

Only if repeat morning testosterone is <300 ng/dL AND patient has specific symptoms:

• Discuss potential benefits (sexual function only), harms, costs, and preferences 1
• If treatment initiated, monitor testosterone levels, PSA, hematocrit, and digital rectal exam at 1-2 months, then 3-6 months for first year, then annually 7
• Reevaluate symptoms at 12 months; discontinue if no improvement in sexual function 1

Summary Algorithm

1. Do NOT start testosterone therapy - levels do not meet diagnostic criteria
2. START high-intensity statin immediately (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)
3. Consider adding ezetimibe 10 mg from the start given high LDL-C and markedly elevated Lp(a)
4. Target LDL-C <55 mg/dL (more aggressive than standard <70 mg/dL due to elevated Lp(a))
5. Recheck CK after 48-72 hours rest to establish true baseline before attributing elevation to statin
6. Repeat testosterone only if clinical suspicion remains after addressing other causes of symptoms
7. Consider PCSK9 inhibitor if LDL-C remains >70 mg/dL on statin + ezetimibe, given the Lp(a) elevation

The elevated Lp(a) is a lifelong, non-modifiable cardiovascular risk factor that makes aggressive LDL-C lowering the absolute priority in this patient. 6